european medicines agency glp-1 vision loss recommendation november 2025 What is the pipeline for future medications for obesity? EMA finds no link between

If your intended use exceeds what is permitted by the license or if you are unable to locate the licence and re-use information, please contact the Rights and Permissions team

L., Thgersen, H., Hansen, B

Commitment to treatment plans is key to success with peptides

Indeed, the antigenic composition of tumors differs significantly from that of their non-transformed tissue counterparts, a distinction largely driven by their genetic instability a core hallmark of cancer ( The concept of immunotherapy builds on the ability of controlling aberrant antigen-induced immune cell activation ( It is now well established that cancer cells can trigger immune responses